Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Reinhardt

Showing results (181-190 of 236) with videos related to

Pageof 24
Sort By:
NPJ Digital Medicine|August 19, 2023
Predicting HPV association using deep learning and regular H&E stains allows granular stratification of oropharyngeal cancer patientsSebastian Klein, Nora Wuerdemann, Imke Demers, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Cell Reports|October 26, 2018
The Cdkn1a<sup>SUPER</sup> Mouse as a Tool to Study p53-Mediated Tumor SuppressionAlessandro Torgovnick, Jan Michel Heger, Vasiliki Liaki, et al.
Cell|July 4, 2015
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant CancerFelix Dietlein, Bastian Kalb, Mladen Jokic, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Nature Communications|December 8, 2025
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancerLydia Meder, Charlotte I Orschel, Cyrielle L Bouchez, et al.
Pageof 24

Showing results (181-190 of 236) with videos related to

Sort By:
Pageof 24
NPJ Digital Medicine|August 19, 2023
Predicting HPV association using deep learning and regular H&E stains allows granular stratification of oropharyngeal cancer patientsSebastian Klein, Nora Wuerdemann, Imke Demers, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Cell Reports|October 26, 2018
The Cdkn1a<sup>SUPER</sup> Mouse as a Tool to Study p53-Mediated Tumor SuppressionAlessandro Torgovnick, Jan Michel Heger, Vasiliki Liaki, et al.
Cell|July 4, 2015
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant CancerFelix Dietlein, Bastian Kalb, Mladen Jokic, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Nature Communications|December 8, 2025
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancerLydia Meder, Charlotte I Orschel, Cyrielle L Bouchez, et al.
Pageof 24